Breadcrumb

[A19-86] Atezolizumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2019-10-07 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 475 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A20-18] Atezolizumab (small cell lung cancer) - Addendum to Commission A19-86
Status: Commission completed

[A19-84] Atezolizumab (NSCLC; combination with nab-paclitaxel and carboplatin) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A19-83] Atezolizumab (NSCLC; combination with bevacizumab, carboplatin and paclitaxel) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A19-81] Atezolizumab (breast cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A18-88] Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V (new scientific findings)
Status: Commission completed

[A18-09] Atezolizumab (non-small cell lung cancer) – Addendum to Commission A17-50
Status: Commission completed

[A17-52] Atezolizumab (urothelial carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A17-51] Atezolizumab (urothelial carcinoma, first-line treatment) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A17-50] Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2020-01-15 Extract of dossier assessment 475 kBPDFdownload file
2020-01-15 Dossier assessment (German version) 4 MBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Atezolizumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V [PDF, 475 kB]

Federal Joint Committee (G-BA)

2020-04-02 A G-BA decision was published.

G-BA documents on this decision



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close